^
Association details:
| Biomarker: | MYCN amplification |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | KB-0742 (CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Regulation of oncogenic transcription and tumor growth in pediatric cancers by the CDK9 inhibitor KB-0742
Published date:
10/12/2022
Excerpt:
In neuroblastoma, cell lines with MYCN amplification were more sensitive to KB-0742 treatment. KB-0742–treated neuroblastoma cells had decreased pSER2, loss of expression of MYCN and MYC, and an induction of cleaved PARP. KB-0742 treatment of a TH-MYCN transgenic mouse model resulted in regression of established tumors. In PDX models of ES and ARMS, KB-0742 treatment inhibited tumor growth.
